C
유틸렉스
263050KOSDAQ기초 의약물질 제조업48.0 / 100
Reference Date: 2026-06-10
Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Utillex is a biotech company established in 2015, focusing on R&D of immunotherapies such as CAR-T and antibody-based treatments. Its key pipeline, EU307, is a 4th-generation armored CAR-T therapy targeting GPC3 in solid tumors, while EU103 converts M2 macrophages to M1 to enhance immune responses, both currently in Phase I clinical trials. The company also operates IT services and research-related business.
Number of Employees
119people
Average Salary
55.5M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 27.714.0Point
PBR
2.24Industry Average 1.742.5Point
Higher than industry avg (caution)
ROE
-88.55Industry Average -6.033.5Point
14.7x industry avg (excellent)
Debt Ratio
21.94Industry Average 6.620.0Point
3.3x industry avg (risky)
Trend 2023~20255.5 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲3572.1% (2-year basis)
Operating Profit Growth Rate
2.5 / 3
Avg ▲19.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -60.4% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (13%, downtrend)
Current 959Won52-week high 2,74052-week low 683
1-month return3.0Point
1m 0% (flat)
Volume trend6.0Point
Volume surge
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral분기보고서 (2026.03)2026-05-14